Replies to post #335 on Longeveron Inc (LGVN)

[hondaboost]

LGVN, actuclly, the news is amazing! $15 million upfront with a milestone-driven potential additional $15 million related to the Company’s anticipated pivotal clinical trial in Hypoplastic Left Heart Syndrome (HLHS) priced at the market under Nasdaq rules